Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population

Overview

Journal Malays J Med Sci

Specialty General Medicine

Date 2013 Sep 18

PMID 24043992

Citations 15

Authors

Paulo Arnaldo

Ricardo Estevao Thompson

Marcia Quinhones Lopes

Philip Noel Suffys

Adalberto Rezende Santos

Affiliations

Soon will be listed here.

Abstract

Background: The cytochrome P450 enzymes (CYP) play an important role in the metabolism of many therapeutic agents. The activities of different enzymes exhibit variability in different populations, which causes variations in drug response or toxicity. The CYP2B6 and CYP2C8 enzymes are encoded by polymorphic genes characterised by different single nucleotide polymorphisms (SNPs). Several of these CYP variants are often associated with slow metabolism phenotypes. This study aimed to analyse the frequencies of allelic variants of CYP2B6 and CYP2C8 in the Mozambican population.

Methods: Using a polymerase chain reaction and restriction fragment length polymorphism assay (PCR-RFLP), the frequencies of the allelic variants of CYP2B6 (c.64C>T, c.516G>T, c.777C>A, c.785A>G, c.1459C>T) and CYP2C8 (c.805A>T, c.416G>A, c.1196A>G, c.792C>G) were determined in 360 Mozambican blood donors.

Results: The frequencies of the allelic variants of the CYP2B6 gene were 0.057, 0.426, 0.0, 0.410, and 0.004. For the CYP2C8 gene, the frequencies of the allelic variants were 0.160, 0.048, 0.0, and 0.005. No significant differences were observed between the gender and geographic distribution of volunteers around the country.

Conclusion: The frequencies of the allelic variants of the CYP2B6 and CYP2C8 genes were found to be homogeneously distributed in the Mozambican population and were comparable to other African populations. Further studies are required to explore the impact of these variants on the clinical response (efficacy and toxicity) of drugs, including antimalarials.

Citing Articles

Association of and Non-Functional Alleles with Ibuprofen-Induced Upper Gastrointestinal Toxicity in a Saudi Patient.

Bagher A Case Rep Med. 2023; 2023:6623269.

PMID: 37520310 PMC: 10382241. DOI: 10.1155/2023/6623269.

Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz.

Mardi P, Tavakoli-Far B, Sheibani Nia S, Jazayeri R, Houshmand M Genet Res (Camb). 2022; 2022:5754776.

PMID: 36320932 PMC: 9605844. DOI: 10.1155/2022/5754776.

Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.

Nthontho K, Ndlovu A, Sharma K, Kasvosve I, Hertz D, Paganotti G Pharmgenomics Pers Med. 2022; 15:613-652.

PMID: 35761855 PMC: 9233488. DOI: 10.2147/PGPM.S308531.

Frequencies of CYP2B64,5, and 6 Alleles within an Iranian Population (Mazandaran).

Hashemi-Soteh M, Hosseini E, Fazelnia S, Ghasemian-Sorbeni F, Madahian S, Shiran M Genet Res (Camb). 2021; 2021:8703812.

PMID: 34949964 PMC: 8660211. DOI: 10.1155/2021/8703812.

Association of Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana.

Maseng M, Tawe L, Thami P, Seatla K, Moyo S, Martinelli A Pharmgenomics Pers Med. 2021; 14:335-347.

PMID: 33758532 PMC: 7981136. DOI: 10.2147/PGPM.S289471.

References

Krishna S, Planche T, Agbenyega T, Woodrow C, Agranoff D, Bedu-Addo G . Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. Antimicrob Agents Chemother. 2001; 45(2):509-16. PMC: 90320. DOI: 10.1128/AAC.45.2.509-516.2001. View

Miksys S, Lerman C, Shields P, Mash D, Tyndale R . Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 2003; 45(1):122-32. DOI: 10.1016/s0028-3908(03)00136-9. View

Svensson U, Ashton M . Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol. 1999; 48(4):528-35. PMC: 2014388. DOI: 10.1046/j.1365-2125.1999.00044.x. View

Li X, Bjorkman A, Andersson T, Gustafsson L, Masimirembwa C . Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003; 59(5-6):429-42. DOI: 10.1007/s00228-003-0636-9. View

Hofmann M, Blievernicht J, Klein K, Saussele T, Schaeffeler E, Schwab M . Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther. 2008; 325(1):284-92. DOI: 10.1124/jpet.107.133306. View

Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C . High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2007; 64(4):357-65. DOI: 10.1007/s00228-007-0412-3. View

Ferreira P, Veiga M, Cavaco I, Martins J, Andersson B, Mushin S . Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit. 2008; 30(1):10-5. DOI: 10.1097/FTD.0b013e31815e93c6. View

Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L . Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007; 81(4):557-66. DOI: 10.1038/sj.clpt.6100072. View

Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy S, Kishikawa Y . Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol. 2002; 58(6):417-21. DOI: 10.1007/s00228-002-0499-5. View

10.

Cavaco I, Stromberg-Norklit J, Kaneko A, Msellem M, Dahoma M, Ribeiro V . CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol. 2005; 61(1):15-8. DOI: 10.1007/s00228-004-0871-8. View

11.

Xie H, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M . Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 2003; 3(1):53-61. DOI: 10.1038/sj.tpj.6500157. View

12.

DeLozier T, Kissling G, Coulter S, Dai D, Foley J, Bradbury J . Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos. 2007; 35(4):682-8. PMC: 2747652. DOI: 10.1124/dmd.106.012823. View

13.

Li X, Bjorkman A, Andersson T, Ridderstrom M, Masimirembwa C . Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002; 300(2):399-407. DOI: 10.1124/jpet.300.2.399. View

14.

Klose T, Blaisdell J, Goldstein J . Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol. 1999; 13(6):289-95. DOI: 10.1002/(sici)1099-0461(1999)13:6<289::aid-jbt1>3.0.co;2-n. View

15.

Guan S, Huang M, Chan E, Chen X, Duan W, Zhou S . Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. Eur J Pharm Sci. 2006; 29(1):14-21. DOI: 10.1016/j.ejps.2006.04.004. View

16.

Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S . Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos. 2003; 31(6):687-90. DOI: 10.1124/dmd.31.6.687. View

17.

Mehlotra R, Ziats M, Bockarie M, Zimmerman P . Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol. 2006; 62(4):267-75. PMC: 4450653. DOI: 10.1007/s00228-005-0092-9. View

18.

Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee B . Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005; 15(1):1-5. DOI: 10.1097/01213011-200501000-00001. View

19.

Lang T, Klein K, Fischer J, Nussler A, Neuhaus P, Hofmann U . Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001; 11(5):399-415. DOI: 10.1097/00008571-200107000-00004. View

20.

Grace J, Aguilar A, Trotman K, Peggins J, Brewer T . Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab Dispos. 1998; 26(4):313-7. View